Category: Press Release - Page 85 - Psychedelic Alpha

Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

Post published:December 9, 2021
Post category:Press Release

Read more about the article atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen atai’s supply chain

atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen atai’s supply chain

Post published:December 9, 2021
Post category:Press Release

Read more about the article MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System

MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System

Post published:December 9, 2021
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Post published:December 8, 2021
Post category:Press Release

Read more about the article Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder

Post published:December 8, 2021
Post category:Press Release

Read more about the article PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States Food and Drug Administration

PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States Food and Drug Administration

Post published:December 7, 2021
Post category:Press Release

Read more about the article Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic Therapies to Treat Substance Use Disorders

Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic Therapies to Treat Substance Use Disorders

Post published:December 7, 2021
Post category:Press Release

Read more about the article Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies

Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies

Post published:December 7, 2021
Post category:Press Release

Read more about the article Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Post published:December 6, 2021
Post category:Press Release

Read more about the article Michael Falvey joins COMPASS Pathways as Chief Financial Officer

Michael Falvey joins COMPASS Pathways as Chief Financial Officer

Post published:December 4, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.